Lilly’s lobbying spending represents a 36-percent drop from the final quarter of 2008, even though the Congressional debate
over health care reform peaked during the last quarter of 2009.
The biggest chance Brad Stevens ever took, the best game plan he ever drew up, had nothing to do with a prized recruit or
some brilliant set of Xs and Os scrawled out on a greaseboard. It came on the day he decided to quit his job at Eli Lilly
and
Co. and to pursue his first love, basketball.
Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
A wave of up-and-coming angel investors in the Indianapolis area are quietly accumulating the expertise and thick wallets
necessary to back startups that are at once risky and rich with potential for lucrative returns.
Dozens of people in the Indianapolis area have the potential and the interest to become angel investors in the next few years.
Eli Lilly and Co. can be certain of its exclusive rights to sell its cancer drug Gemzar for at least another
seven months. After that, who knows? The U.S. District Court for the Southern District of Indiana last week upheld the validity
of Lilly’s compound patent on Gemzar. But the court said Indianapolis-based Lilly could not enforce a second patent
on the drug until a court challenge plays out. That patent, related to the particular way Gemzar is used, was declared invalid
last year by a federal court in Michigan. Lilly's appeal of the Michigan ruling to the Court of Appeals for the Federal
Circuit will be heard on May 7. At stake is another three years of exclusive sales of Gemzar, if Lilly’s second patent
is upheld.
Indianapolis-based OneAmerica Financial Partners Inc. is edging further into the employee-benefits market.
The company’s American United Life Insurance Co. will now offer vision and dental insurance to its employer customers.
AUL won’t underwrite the insurance itself, instead hawking policies from Minnesota-based Security Life Insurance Company
of America. AUL will act as the third-party administrator for the policies it sells. AUL already offers disability, medical
stop-loss and group life insurance to employers.
Purdue University's Healthcare Technical Assistance Program has named Monica Arrowsmith director of
a new center to help Indiana primary-care doctors adopt electronic record and e-prescribing technology. Arrowsmith is heading
the Indiana Health Information Technology Extension Center (I-HITEC), funded by $12 million in stimulus funds via a federal
grant. Purdue’s center, one 70 nationwide to receive stimulus funds, will help small practices of 10 or fewer health
care providers select and implement new information technology. Arrowsmith was chief quality officer and legal counsel for
Clarian Arnett Health in Lafayette.
IUPUI is offering a new online graduate certificate program in clinical informatics to help local health
care providers use the information provided by electronic medical record systems to improve their practices. The certificate
can be gained by taking six courses available in the evening and accessible through online distance education. Applicants
must have clinical backgrounds, be licensed and hold a four-year degree from an accredited institution.
Four-year agreement to provide engines for tanker aircraft is the latest military contract snared by Rolls-Royce’s local operations.
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
Once-weekly form of Byetta is awaiting the FDA’s OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
Work force reductions, new business structure make leased office space unnecessary. Moves will begin in late June.
Indianapolis-based Strand Analytical Laboratories LLC sold its paternity and immigration DNA testing unit
to Orchid Cellmark Inc., a New Jersey company with annual revenue of $450,000. Financial terms were not disclosed.
Beginning in late June, Eli Lilly and Co. will move all 1,000 employees at its Faris campus on South Meridian
Street in Indianapolis to its Lilly Corporate Center complex on McCarty Street. Lilly’s ongoing staff cuts have reduced
its need for the Faris space, and the Indianapolis company wants to locate its employees on the same campus as part of a new
business structure. The company hired CB Richard Ellis in August to lease the 465,000 square feet on the Faris campus. Lilly
first said in October that it would move all 1,000 employees out of the Faris complex. The campus opened in late 2002.
Purdue University has received $14.9 million in federal stimulus funding from the National Institutes of
Health to expand its Bindley Bioscience Center for cancer and life sciences research in West Lafayette. Purdue expects to
hire 30 to 40 people to conduct federally funded research on animals at the center once the expansion opens in April 2013.
The 29,000-square-foot addition will be called the Multidisciplinary Cancer Research Facility at Purdue. Construction is set
to begin in August. The Bindley Bioscence Center, located on Purdue’s Discovery Park research campus, opened in 2005.
The existing facility is 50,000 square feet.
Historic Landmarks' endowment is down sharply, but executives believe they can afford to take on the cultural-events-center
project.
As shareholders gather April 19 for Eli Lilly and Co.’s annual meeting, more of them than ever will come with an unusual question:
Will Lilly be able to keep paying its dividend?
The Indianapolis-based drugmaker also lowered its forecast for full-year profits because the new health care law grants bigger
rebates on prescription drugs to federal health insurance programs.
Lilly shareholders are set to gather Monday in Indianapolis to hear an update on the company’s performance, including
how it will keep paying its generous dividend during the lean years after Zyprexa’s patent expiration.
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European
partner Boehringer Ingelheim for an initial payment of $400 million.
The proposal to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board received
approval from shareholders holding 74 percent of Lilly’s shares.
The national unemployment rate for college graduates age 25 and older was 4.9 percent in March, up from 4.4 percent a year
ago, the U.S. Bureau of Labor Statistics reports.
